- Conditions
- Liver Disease, Liver Transplantation
- Interventions
- Alemtuzumab, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Liver transplant, Immunosuppression withdrawal
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Miami, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 565
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- Up to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dry Eye, Meibomian Gland Dysfunction
- Interventions
- TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- Device · Drug
- Lead sponsor
- Sight Sciences, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
- Conditions
- Aplastic Anemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Marrow Transplantation, Computed Tomography, Cyclosporine, Fludarabine, Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Ruxolitinib, Sirolimus, Total-Body Irradiation, Multigated Acquisition Scan, Echocardiography
- Procedure · Drug · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Dry Eye Disease
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Liver Transplantation
- Interventions
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, methylprednisolone, bone marrow ablation with stem cell support, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 5 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 2 more
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Renal Transplantation
- Interventions
- Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Fungal Keratitis, Corneal Ulcer
- Interventions
- Cyclosporine A, Placebo Comparator: Placebo
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graft Versus Host Disease, Lymphoma
- Interventions
- aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Mycophenolate Mofetil, Sirolimus
- Procedure · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- cyclosporine, ticagrelor
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
- Interventions
- cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- filgrastim, busulfan, cyclophosphamide, cyclosporine, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Renal Transplantation
- Interventions
- Corticosteroid withdrawal
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Kidney Transplantation, Chronic Kidney Failure
- Interventions
- Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
- Conditions
- Vernal Keratoconjunctivitis
- Interventions
- NOVA22007 ''Ciclosporin'', Placebo
- Drug
- Lead sponsor
- Santen SAS
- Industry
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
- Conditions
- Dry Eye
- Interventions
- Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
- Drug
- Lead sponsor
- Research Insight LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Hemet, California • Laguna Hills, California • Brecksville, Ohio
- Conditions
- Ocular Surface Disease
- Interventions
- cyclosporine ophthalmic emulsion 0.05%
- Drug
- Lead sponsor
- Boston Sight
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Needham, Massachusetts
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Corneal Transplantation, Corneal Graft Rejection
- Interventions
- LX201, Placebo
- Drug · Other
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
- Conditions
- Graft Vs Host Disease
- Interventions
- Subconjunctival Cyclosporine Implant
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 9 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland